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Abstract
Background: Multicentric Castleman’s disease (MCD) is characterized by a systemic lymphoproliferative disorder
affecting systemic lymph nodes. Cerebrovascular involvements have rarely been reported, and to our knowledge,
cerebral angiitis causing subarachnoid hemorrhage (SAH) in patients with Multicentric Castleman’s disease (MCD)
has not been previously described.
Case presentation: We identified two cases of MCD with SAH who were receiving immunosuppressive therapy
with low dose prednisolone. Both patients presented with sudden-onset headache and were diagnosed with
cortical SAH in the sulci by a computed tomography scan. Digital subtraction angiography showed segmental
stenosis in the peripheral area of the middle cerebral artery. In both cases, cerebral angiitis causing SAH induced by
a systemic inflammatory condition and elevated levels of interleukin (IL) -6 were suspected and resolved over a
period of several months.
Conclusion: Our cases highlight the clinical diversity of the potential causes of cerebral angiitis and expand the
association of MCD and cortical SAH; however, cortical SAH patients have a more favorable outcome than
aneurysmal SAH patients.
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Background
Castleman’s disease (CD) was initially described by Ben-
jamin Castleman et al. in 1956 as a disease with solitary
hyperplastic mediastinal lymph nodes containing small,
hyalinized follicles and a marked interfollicular vascular
proliferation [1]. CD is caused by infection of human
herpesvirus 8 (HHV-8) and human immunodeficiency
virus (HIV). Such viral infections cause B cells in the
lymph nodes to excessively release interleukin (IL) -6 or
similar polypeptides and cause several autoimmune clin-
ical symptoms [2]. CD is classified into two subgroups,
unicentric Castleman’s disease (UCD) and multicentric
Castleman’s disease (MCD). UCD usually affects one
lymph node area and the patients are often asymptom-
atic. In contrast, MCD affects systemic lymph nodes and
the patients present various symptoms, such as
hyperthermia, lymphadenopathy, splenomegaly, hepato-
megaly, pulmonary disorders, edema, and ascites. MCD
also may be associated with a variety of malignant dis-
eases, such as Kaposi sarcoma, non-Hodgkin lymphoma,
Hodgkin lymphoma, POEMS syndrome: polyneuropathy,
organomegaly, endoclinopathy, monoclonal proteinemia
and skin changes [2]. About the vascular involvements
of MCD, temporal arteritis [3] and some cases of coron-
ary and lower limb vascular involvements have been de-
scribed. In general, it is unusual that the patients of
MCD will present neurological symptoms, and intracra-
nial involvements of the MCD have been rarely reported
in the literature to date [4]. An association of MCD with
some types of intracranial tumors, such as chordoid
meningioma and clear cell meningioma, has been re-
ported in some cases [5]. The pathogenesis of MCD in
cases with such intracranial tumors remains unclear, but
a complex cytokine network, including IL-6, IL-1β and
vascular endothelial growth factor (VEGF), may contrib-
ute to the growth of the tumor [6]. Although there are
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some reports of cerebrovascular involvements in patients
with MCD, all of the presented cases had ischemic
stroke caused by cerebral angiitis secondary to a sys-
temic inflammatory condition, as indicated by excessive
serum levels of IL-6 [7, 8]. To our knowledge, no reports
are currently available about cerebral angiitis causing
subarachnoid hemorrhage (SAH) in patients with MCD.
Here, we describe two rare cases of MCD associated
with cerebral angiitis leading to SAH.
Case presentation
Case 1
A 57-year-old woman was admitted to a nearby hospital
because of respiratory discomfort due to exercise, where
a laboratory examination showed high levels of serum
gamma globulin. She was then referred to our hospital
for further examination. On admission, her physical
examination showed a swelling of the lymph nodes of
the mediastinum and axillary fossa. Laboratory examin-
ation showed anemia (hemoglobin: 3.9 g/dl), hypoalubu-
minemia (1.5 g/dl), hypergammaglobulinemia (IgG:
8140 mg/dl, normal: 870–1700 mg/dl, IgA: 851 mg/dl,
normal: 110–410 mg/dl, IgM: 297 mg/dl, normal: 46–
260 mg/dl) and an elevation of serum levels of C-
reactive protein (CRP) (9.8 mg/dl). The serum IL-6 level
was 43.5 pg/ml (normal < 4.0 pg/ml). An HIV viral
examination was negative. HHV-8 examination was un-
done. A chest X-ray showed a reticular shadow of bilat-
eral lung fields. Histopathological examination by
transbronchial lung biopsy (TBLB) to lung lesions
showed plasmacystic proliferation. The histopatho-
logical findings led to her to be diagnosed as MCD,
and we started to administrate prednisolone orally
(50 mg/day). Thrombocytopenia or coagulopathy
(including anticoagulant-induced) was not identified
based on the laboratory findings, and any other infec-
tion or autoimmune disorder was excluded. Three
months after admission to our hospital, she suddenly
felt a strong headache. She was alert and presented
no apparent neurological deficit. The level of immu-
noglobulins and other laboratory findings were similar
to those recorded previously. Her blood pressure was
148/88 mmHg, and her other vital signs were within
normal range. A head computed tomography (CT) scan
showed cortical SAH along the left frontal sulci (Fig. 1a).
Further evaluation by fluid-attenuated inversion recovery
Fig. 1 Neuroimaging findings of Case 1. a CT scan of the head shows a cortical subarachnoid hemorrhage along the left frontal sulci (arrow
heads). b FLAIR sequence of the MRI shows the distribution of a subarachnoid hemorrhage (arrow heads) and hyperintense signal in the
cortical-subcortical regions of the right parietal lobe (arrow). c Lateral view of the left internal carotid angiogram shows stenosis in the area of the
peripheral middle cerebral artery. d Lateral view of the left internal carotid angiogram obtained ten days after onset shows diffuse segmental
stenosis in the area of both the anterior and middle cerebral artery
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(FLAIR) sequence of magnetic resonance imaging (MRI)
showed the distribution of SAH and a hyperintense signal
in the cortical-subcortical regions of the right parietal lobe
(Fig. 1b). The corresponding diffusion-weighted images
(not shown) were normal. We performed digital subtrac-
tion angiography (DSA) emergently to search for the
source of bleeding. We could not find vascular abnormal-
ities, but we did find segmental stenosis and delayed flow
of the left middle cerebral artery (MCA) (Fig. 1c). We
diagnosed that the stenosis due to angiitis caused both
SAH and ischemic change, and we performed antihyper-
tensive therapy by infusion of a calcium-channel blocker.
The follow-up DSA obtained after ten days from onset
showed newly segmental stenosis of the anterior cerebral
artery (ACA) and progression of the stenosis of the MCA
(Fig. 1d). Angiography of the bilateral renal artery in the
same examination also showed stenosis of the peripheral
renal artery (not shown). These results indicated that
systemic angiitis associated with MCD might have
occurred, and we continued prednisolone therapy
(decreased to 22.5 mg/day). Fortunately, she did not
present neurological focal deficit including high function
disorder, and her headache became weakened day by day.
SAH completely disappeared and no de novo stenosis of
intracranial artery in the other portion by 1 month,
as determined by MRI, and no other event was recognized
during an 8-year follow-up period.
Case 2
A 59-year-old woman found a rash on her abdomen
20 years ago. At 51 years of age, she was diagnosed with
anemia and hypergammaglobulinemia at an annual
health checkup. For further examination, she was admit-
ted to a general hospital near her home. There, a phys-
ical examination did not find swelling of lymph nodes or
any other abnormal findings. A laboratory examination
found anemia (hemoglobin: 9.1 g/dl), hypoalubuminemia
(2.1 g/dl), hypergammaglobulinemia (IgG: 6627 mg/dl,
IgA: 798 mg/dl, IgM: 765 mg/dl) and an elevation of
serum levels of CRP (9.8 mg/dl) and the serum IL-6
level (131 pg/ml). HIV viral examination was negative.
HHV-8 examination was undone. Past examinations
showed that she had neither thrombocytopenia nor co-
agulopathy. A chest and abdominal CT scan showed an
interstitial shadow at the bilateral lung fields and mild
splenomegaly. Biopsy of the lesion showed the prolifera-
tion of plasmacyte around vessels within true skin. She
was diagnosed with MCD at 57 years old and started
oral prednisolone (20 mg/day). At 58 years of age, she
was introduced to our hospital because she moved to a
home and continued prednisolone therapy. The condi-
tion of the disease was relatively stable, but the long-
term administration of prednisolone was expected to
risk systematic complications. We started to infuse
tocilizumab, a humanized anti-human IL-6 receptor
antibody, and decreased the dose of prednisolone to
12.5 mg/day. One day, she was admitted to the emer-
gency room of our hospital complaining of sudden-on-
set headache, and she was alert and presented no appar-
ent neurological deficit. Her blood pressure was rela-
tively high (180/90 mmHg), and other laboratory
findings, including the level of immunoglobulin E, were
almost within normal ranges. Head CT showed subtle
cortical SAH along the right parietal sulci (Fig. 2a).
FLAIR images showed the distribution of cortical SAH
in right parietal sulci (Fig. 2b). The emergent right in-
ternal cerebral angiography, late arterial phase, showed
stenosis and post-stenotic delayed opacification in the
area of the peripheral middle cerebral artery; this perfu-
sion area corresponded to the location of SAH (Fig. 2c).
The follow-up DSA after one week after onset showed
the disappearance of both stenosis and disturbed perfu-
sion (Fig. 2d), and her headache got better and also the
focal deficit was not presented. After 1-year from the
discharge, cortical SAH was completely disappeared and
no other vascular lesion was detected by the follow-up
MRI, and no other event was recognized in the follow-
up period.
Discussion
Only in some cases in MCD, the cerebrovascular in-
volvements of ischemic stroke due to cerebral angiitis
have been reported, especially in the cases of MCD with
POEMS syndrome [7, 8]. Rössler M et al. reported on a
case of young female with POEMS syndrome presented
recurrent ischemic stroke due to cerebral vasculitis. In
this case, DSA showed the segmental stenosis of prox-
imal ACA [9]. Garcia T et al. described two cases of
POEMS syndrome and MCD accompanied with recur-
rent ischemic stroke, in which DSA showed diffuse non-
atherosclerotic segmental stenosis of the intracranial ar-
teries. They hypothesized that the stenosis might be in-
duced by the overproduction of cytokines, such as IL-6,
IL-1β and VEGF in MCD, however they concluded the
pathogenesis remained unclear [10]. Among these in-
flammatory biomarkers, IL-6 is well known to play an
important role in acute inflammatory response triggered
by cerebral ischemia, and an elevated blood IL-6 con-
centration is associated with poor outcome after stroke
[11]. Moreover, a higher level of serum IL-6 is also asso-
ciated with an increased risk of recurrent vascular events
after stroke [9]. Despite these conclusive findings in both
acute and chronic phases that clearly indicate an import-
ant role of IL-6 in stroke patients, these associations are
not fully understood. According to these reports, ele-
vated levels of IL-6 might be a major causal factor in the
occurrence of cerebral angiitis in our patients with MCD
and a lasting chronic over-expression of IL-6. Further
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research is required to substantiate the role of these bio-
markers and to determine whether any of them may
serve as a prognostic factor or therapeutic target to pre-
vent cerebral angiitis in MCD.
On the other hand, there is no report of hemorrhagic
stroke due to cerebral angiitis in patients with MCD. In
our two cases of MCD accompanied with SAH, it is
pathognomonic that both cases presented with cortical
SAH isolated along sulci, and both cases are accompan-
ied with the segmental stenosis of peripheral intracranial
arteries. The stenosis in these cases may be due to angii-
tis and SAH induced by the vulnerability of the arterial
wall. This hypothesis is supported by the fact that the
angiographic findings of angiitis appeared not only in
intracranial arteries but also in bilateral renal arteries in
case 1. As previously reported, the prognosis of patients
with cortical SAH carried a favorable outcome than that
of aneurysmal SAH [12]. Despite the presence of severe
vasoconstriction, ischemic stroke, and cortical SAH, our
case also experienced a favorable outcome, so a noninva-
sive imaging work-up, such as CT angiography or MR
angiogram, should be introduced after an initial DSA
does not identify any other underlying etiology.
Because there is no conclusive test that can be used to
diagnosis cerebral angiitis, it is crucial to exclude the many
other conditions that can mimic the symptoms of cerebral
angiitis. First, patients with clinical and imaging features,
such as severe headache, variable neurological deficits,
and reversible arterial abnormalities (dilatations and sten-
osis), can be separately recognized as the reversible cere-
bral vasoconstriction syndrome (RCVS). Approximately
one-third of patients with RCVS develop ischemic stroke,
lobar hemorrhage, or convexal SAH. RCVS-related SAH
likely results from dynamic caliber changes affecting cor-
tical surface vessels, and it is also usually restricted to 1 to
2 sulcal spaces [13]. In our cases, reversible imaging find-
ings were compatible with RCVS; however, we believe that
the systemic inflammatory condition (i.e., MCD) possibly
explained the reversible vasoconstriction. Second, the
stenosis of intracranial arteries may be the ultra-early
vasospasm that occurred immediately after SAH. Qurehi
AI et al. reported in their study that 13 % of patients had
evidence of ultra-early vasospasm (within the first 48 h),
and the vasospasms were mild (vessel narrowing of 25–
50 %) in 78 % of these patients [14]. Although immediate
vasospasm of cortical SAH has been suspected, coexist-
ence with these has never been reported in the literature.
A possible explanation of this was that a small amount of
extravascular blood of the cortical SAH has less local ef-
fect on cerebral arteries compared to aneurysmal one.
Fig. 2 Neuroimaging findings of Case 2. a CT scan of the head shows a subtle cortical subarachnoid hemorrhage along the right parietal sulci
(arrow heads). b FLAIR sequence of the MRI shows the distribution of a subarachnoid hemorrhage (arrow heads). c Lateral magnified view of the
right internal carotid angiogram, late arterial phase, shows a stenosis (arrow) and post-stenotic delayed opacification in the area of peripheral
middle cerebral artery. d Lateral magnified view of the right internal carotid angiogram obtained one week after onset shows a disappearance of
stenotic findings and normal perfusion (arrow)
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Third, the long-term administration of glucocorticoid may
also introduce the atherosclerotic stenosis of intracranial
arteries. In such a case, the stenosis should not be seg-
mental but widespread to all intracranial arteries, and we
believe that it is difficult for the stenosis to recovery angio-
graphically in such a short period. Moreover, the symp-
toms present relative slowly, not drastically. At present,
we require additional careful considerations that distin-
guish RCVS or other possible causes from these systemic
conditions until further studies can be performed.
Conclusions
We identified two cases of MCD who presented with
sudden-onset headache and were diagnosed with cortical
SAH. In both cases, cerebral angiitis causing SAH in-
duced by a systemic inflammatory condition due to
MCD. Our cases highlight the clinical diversity of the
potential causes of cerebral angiitis and expand the asso-
ciation of MCD and cortical SAH.
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